Prostaglandins as modulators of immunity

Trends in Immunology

Volumn 23, Issue 3, 2002, Pages 144-150

  Harris, Sarah G ^a   Padilla, Josue ^a   Koumas, Laura ^a   Ray, Denise ^a   Phipps, Richard P ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2;

BLADDER CANCER; BREAST CANCER; CANCER GROWTH; COLON CANCER; ESOPHAGUS CANCER; HUMAN; IMMUNITY; IMMUNOREGULATION; INFLAMMATION; LUNG CANCER; NONHUMAN; PERIODONTAL DISEASE; PROSTATE CANCER; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DINOPROSTONE; HUMANS; INFLAMMATION; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; NEOPLASMS; PROSTAGLANDIN D2; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036499224     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(01)02154-8     Document Type: Review

References (70)

1. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases
2. A new view of prostaglandin-E regulation of the immune response
3. Pharmacology of prostaglandin endoperoxide synthase isozymes 1 and 2
4. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis
5. Cyclooxygenase-2: Molecular biology, pharmacology and neurobiology
6. Molecular cloning and induction of bovine prostaglandin E synthase by gonadotropins in ovarian follicles prior to ovulation in vivo
7. Prostanoid receptors. Structure, function and distribution
8. Prostanoid receptors: Subtypes and signaling
9. Expression of the prostaglandin E(2) [PGE(2)] receptor subtype EP(4) and its regulation by PGE(2) in osteoblastic cell lines and adult rat bone tissue
10. Mixed messages: Modulation of inflammation and immune responses by prostaglandins and thromboxanes
11. 4 in the nuclear envelope
12. 2-treated human T lymphocytes
13. 2+ mobilization in T cells
14. PGE(2)-mediated inhibition of T-cell p59 (fyn) is independent of cAMP
15. Prostanoids in human colonic mucosa: Effects of inflammation on PGE(2) receptor expression
16. 2 in vivo
17. 2 induces apoptosis in resting immature and mature human lymphocytes: A c-Myc-dependent and Bcl-2-independent associated pathway
18. 2 inhibits T-cell-activation-induced apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand induction
19. Modulation of T-cell cytokine secretion by accessory-cell-derived products
20. 2 enhancement of interferon-γ production by antigen-stimulated type 1 helper T cells
21. 2 is variably induced by bacterial superantigens in bovine mononuclear cells and has a regulatory role for the T-cell proliferative response
22. Regulation of TCR-induced IFN-γ release from islet-reactive non-obese diabetic CD8(+) T cells by prostaglandin E(2) receptor signaling
23. 2 on the growth and differentiation of human B lymphocytes activated through their CD40 antigen
24. 2 induces apoptosis in immature normal and malignant B lymphocytes
25. Prostaglandin E(2) and stem-cell factor can deliver opposing signals to B-lymphocyte precursors
26. 4 subtypes regulate B-lymphocyte activation and differentiation to IgE-secreting cells
27. Biphenotypic B/macrophage cells express COX-1 and up-regulate COX-2 expression and prostaglandin E(2) production in response to pro-inflammatory signals
28. Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells
29. 2, promote Th2 responses
30. Prostaglandin E(2) upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages
31. 4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages
32. Regulation of TNF-α and interleukin-10 production by prostaglandins I(2) and E(2): Studies with prostaglandin-receptor-deficient mice and prostaglandin-E-receptor subtype-selective synthetic agonists
33. Salicyclate metabolites inhibit cyclooxygenase-2-dependent prostaglandin E(2) synthesis in murine macrophages
34. Non-steroidal anti-inflammatory drugs as inhibitors of periodontal disease progression
35. Role of cytokines and inflammatory mediators in tissue destruction
36. Cyclooxygenase-2-dependent prostaglandin production by peripheral-blood monocytes stimulated with lipopolysacharides isolated from periodontopathogenic bacteria
37. Cyclooxygenase-2: A novel target for cancer chemotherapy?
38. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice
39. 2 production
40. The contributions of cyclooxygenase-2 to tumor angiogenesis
41. Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition
42. Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4) and taurocholate
43. The nuclear receptor PPAR-γ - Bigger than fat
44. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
45. The nuclear receptor PPAR-γ is expressed by mouse T lymphocytes and PPAR-γ agonists induce apoptosis
46. The nuclear receptor PPAR-γ and immunoregulation: PPAR-γ mediates inhibition of helper T-cell responses
47. 2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells
48. 2 inhibits the β2-integrin-dependent oxidative burst: Involvement of a mechanism distinct from peroxisome proliferator-activated receptor γ ligation
49. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
50. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seven-transmembrane receptor CRTH2
51. Inhibition of IκB kinase and IκB phosphorylation by 15-deoxy-Δ(12,14)-prostaglandin J(2) in activated murine macrophages
52. Peroxisome proliferator activator receptor γ agonists and 15-deoxy-Δ(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells
53. Endogenous PPAR-γ mediates anti-inflammatory activity in murine ischemia-reperfusion injury
54. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
55. 15-deoxy-Δ(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
56. Interleukin-1β induces type-II-secreted phospholipase A(2) gene in vascular smooth muscle cells by a nuclear factor κB and peroxisome proliferator-activated receptor-mediated process
57. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells
58. 2
59. A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPAR-γ
60. 2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-γ-independent manner
61. Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo
62. PPAR-γ ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell-cycle arrest and reduction of ornithine decarboxylase activity
63. A nuclear receptor in thyroid malignancy: Is PAX8/PPAR-γ the Holy Grail of follicular thyroid cancer?
64. 2
65. 2 in transgenic adenocarcinoma of mouse prostate cells
66. Loss-of-function mutations in PPAR-γ associated with human colon cancer
67. The nuclear eicosanoid receptor, PPAR-γ, is aberrantly expressed in colonic cancers
68. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor γ ligand troglitazone in patients with liposarcoma
69. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo
70. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells